Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 2
2015 3
2016 2
2017 4
2018 8
2019 12
2020 12
2021 12
2022 12
2023 15
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Results by year

Filters applied: . Clear all
Page 1
Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma.
Sun G, Chen J, Liang J, Yin X, Zhang M, Yao J, He N, Armstrong CM, Zheng L, Zhang X, Zhu S, Sun X, Yang X, Zhao W, Liao B, Pan X, Nie L, Yang L, Chen Y, Zhao J, Zhang H, Dai J, Shen Y, Liu J, Huang R, Liu J, Wang Z, Ni Y, Wei Q, Li X, Zhou Q, Huang H, Liu Z, Shen P, Chen N, Zeng H. Sun G, et al. Nat Commun. 2021 Sep 6;12(1):5262. doi: 10.1038/s41467-021-25618-z. Nat Commun. 2021. PMID: 34489456 Free PMC article.
Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma.
Liang J, Sun G, Pan X, Zhang M, Shen P, Zhu S, Zhao J, Zheng L, Zhao J, Chen Y, Yin X, Chen J, Hu X, Zeng Y, Chen J, Wang Y, Liu Z, Yao J, Su M, Huang R, Liao B, Wei Q, Li X, Zhou Q, Liu J, Shen Y, Liu Z, Chen N, Zeng H, Zhang X. Liang J, et al. Among authors: sun g. Genome Med. 2023 May 2;15(1):31. doi: 10.1186/s13073-023-01182-7. Genome Med. 2023. PMID: 37131267 Free PMC article.
Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma.
Sun G, Zhang X, Liang J, Pan X, Zhu S, Liu Z, Armstrong CM, Chen J, Lin W, Liao B, Lin T, Huang R, Zhang M, Zheng L, Yin X, Nie L, Shen P, Zhao J, Zhang H, Dai J, Shen Y, Li Z, Liu J, Chen J, Liu J, Wang Z, Zhu X, Ni Y, Qin D, Yang L, Chen Y, Wei Q, Li X, Zhou Q, Huang H, Yao J, Chen N, Zeng H. Sun G, et al. Clin Cancer Res. 2021 Mar 15;27(6):1734-1743. doi: 10.1158/1078-0432.CCR-20-3788. Epub 2021 Jan 7. Clin Cancer Res. 2021. PMID: 33414138
Genomic and Evolutionary Characterization of Concurrent Intraductal Carcinoma and Adenocarcinoma of the Prostate.
Zhao J, Xu N, Zhu S, Nie L, Zhang M, Zheng L, Cai D, Sun X, Chen J, Dai J, Ni Y, Wang Z, Zhang X, Liang J, Chen Y, Hu X, Pan X, Yin X, Liu H, Zhao F, Zhang B, Chen H, Miao J, Qin C, Zhao X, Yao J, Liu Z, Liao B, Wei Q, Li X, Liu J, Gao AC, Huang H, Shen P, Chen N, Zeng H, Sun G. Zhao J, et al. Among authors: sun g. Cancer Res. 2024 Jan 2;84(1):154-167. doi: 10.1158/0008-5472.CAN-23-1176. Cancer Res. 2024. PMID: 37847513
Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P).
Zhu S, Zhao J, Nie L, Yin W, Zhang Y, Zhao F, Ni Y, Zhang X, Wang Z, Dai J, Liu Z, Chen J, Zeng Y, Wang Z, Sun G, Liang J, Zhao X, Zhu X, Tao R, Yang J, He B, Chen N, Shen P, Zeng H. Zhu S, et al. Among authors: sun g. BMC Med. 2022 Jul 22;20(1):237. doi: 10.1186/s12916-022-02430-0. BMC Med. 2022. PMID: 35864546 Free PMC article.
Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase-Deficient Renal Cell Carcinoma.
Chen J, Hu X, Zhao J, Yin X, Zheng L, Guo J, Chen J, Wang Y, Sheng X, Dong H, Liu X, Zhang X, Liang J, Liu H, Yao J, Liu J, Shen Y, Chen Z, He Z, Wang Y, Chen N, Nie L, Zhang M, Pan X, Chen Y, Liu H, Zhang Y, Tang Y, Zhu S, Zhao J, Dai J, Wang Z, Zeng Y, Wang Z, Huang H, Liu Z, Shen P, Zeng H, Sun G. Chen J, et al. Among authors: sun g. Clin Cancer Res. 2024 Jun 3;30(11):2571-2581. doi: 10.1158/1078-0432.CCR-23-2760. Clin Cancer Res. 2024. PMID: 38512114 Free PMC article.
Neuroendocrine differentiation predicts the therapeutic efficacy of abiraterone and docetaxel as first-line therapy in metastatic castration-resistant prostate cancer.
Xu N, Zhao J, Zhao F, Liu H, Yin W, Zhu S, Nie L, Sun G, Zheng L, Liu Z, Cai D, Chen J, Dai J, Ni Y, Wang Z, Zhang X, Liang J, Chen Y, Hu X, Pan X, Yin X, Zhu X, Zhang Y, Wang Z, Zeng Y, Wang M, Shen P, Chen N, Zeng H. Xu N, et al. Among authors: sun g. J Cancer Res Clin Oncol. 2023 Aug;149(10):7247-7258. doi: 10.1007/s00432-023-04639-9. Epub 2023 Mar 13. J Cancer Res Clin Oncol. 2023. PMID: 36907910
81 results